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Drugs may stimulate the immune system by forming haptenecarrier complexes or via their pharma-
cological features, namely by noncovalent binding to proteins such as immune receptors. The latter type
of immune stimulation is called the p-i concept, meaning pharmacological interaction with immune
receptors, which implies stimulation of the immune system by noncovalent binding of a drug to T-cell
receptors for antigens (p-i TCR) or human leukocyte antigens (p-i HLA). The functional consequences of
these interactions are heterogeneous: clinically, it can lead to T-cell mediated reactions such as Stevens
eJohnson syndrome/toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms,
acute generalized exanthematous pustulosis, and maculopapular eruptions. If the drug binds to the TCR,
it can become stimulatory, and an additional interaction with HLA/peptide complexes is necessary for full
stimulation. The T-cell reaction can be oligoclonal or polyclonal. Binding of drugs to an HLA molecule can
have two consequences: if the drug can modify the HLA molecule, a distinct repertoire of peptides might
be presented: this is the altered peptide model. However, peptide exchange is not necessary to make the
peptide-HLA complex immunogenic: if the drug binds to HLA, already the complex of altered HLA and
normal peptide is immunogenic and able to stimulate T-cells (altered peptide-HLA model). The immu-
nological and clinical consequences of different forms of the p-i concept are described with typical p-i
binding drugs such as abacavir, carbamazepine, ﬂucloxacillin, allopurinol, and sulfamethoxazole. Thereby
the role of drug binding to HLA or TCR, the afﬁnity of drug binding, additional TCR binding, and potential
oligoclonality are described and compared.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Drug hypersensitivity (DH) reactions are a modern and largely man
made (iatrogenic) heterogeneous group of diseases, linked to the
wide use of chemicals that are orally, parentally, or locally/topically
applied. DH represents only a part of drug-related side effects. It is
usually described as unpredictable and the clinical picture is not
explained by the drug action or underlying disease: these unex-
pected clinical manifestations and the sometimes fulminant course
make it an enigmatic area for clinicians and researchers. In addi-
tion, in DH, two highly variable systems meet: on one hand the
endless number of novel small molecules, the majority chemicallyy and Allergology, University
iwanese Dermatological Associatiosynthesized; and on the other, the highly variable immune system
with > 1011 different T-cell receptors (TCRs) and antibodies per
individual, and a large number of human leukocyte antigens (HLA)
molecules (> 9300) in the population (http://www.ebi.ac.uk/imgt/
hla/stats.html).
The predominant antigens for both T-cells/TCRs, as well as B-
cells/immunoglobulins, are proteins; in particular structural or
sequential epitopes [mostly 8w20-amino acid (AA) long peptide
stretches] within or derived from larger proteins. The highly vari-
able immune receptors are supposed to not interact with small
molecules (< 1000 Da), as the high speciﬁcity of the immune re-
ceptors requires a certain size of its antigens to be recognized as
antigen and be differentiated from other structures. If the antigen
was very small, e.g. methanol (CH3OH), it could bind to many
different regions within the protein receptor. However, even if it
would ﬁt into the receptor binding site, it would probably notn. Published by Elsevier Taiwan LLC. All rights reserved.
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further checkpoint to exclude small molecules from activating the
immune system is the need for cross-linking immune receptors to
elicit an effector mechanism. Small molecules are too small to
cross-link two adjacent immunoglobulins and their Fc-IgE-
receptors; thus no cell signaling occurs.
In spite of these limitations, there are enough examples of drugs
eliciting DH, drug-induced autoimmunity, and drug-induced im-
munodeﬁciency. Until recently, all these immune interactions were
explained by the hapten features of the drug or drug metabolite
(see below). However, during the last 15e20 years it has become
clear that drugs have more possibilities to interact with the im-
mune system than just by inducing an immune reaction by forming
haptenecarrier complexes1e10: drugs are able to stimulate the
innate immune system by binding to TLR (imiquimod),1 drugs can
bind to major histocompatibitlity complex (MHC) molecules and
interfere with peptide loading onto MHCs (MHC loading enhancer,
MLE),2 which is similar to the altered peptide hypothesis, where
drug binding to certain HLA alleles may affect the presentation of
peptides presented by a certain allele.3e5 In addition, drugs may
also bind directly to a TCR and stimulate, in the presence of HLA/
peptide interactions, speciﬁc T-cells via TCR.6,7 The latter concepts,
drug binding to the TCR or HLAwith functional consequences, were
originally described as pharmacological interactions of drugs with
immune receptors (p-i concept).8e10 In this review I will analyze
brieﬂy the hapten and prohapten concept, the initial ﬁndings
leading to the p-i concept, the reﬁnement of p-i (TCR) and p-i (HLA)
concepts and extensions as elaborated during the last years. I
compare immune stimulations by drug binding to TCR or HLA and
their functional consequences and illustrate different possibilities
of p-i using different drugs. Importantly, I indicate the possibility
that peptide exchange is not a prerequisite of p-i (HLA) stimulations
elicited by drugs, as drug binding to HLA per se already forms a
highly immunogenic structure, which leads to strong T-cell acti-
vation in the presence of normal peptides (altered pHLA). Com-
parison of the hapten and p-i concepts is summarized in Table 1.The hapten concept
The limited interactions of small molecules with the immune sys-
tem have been recognized by studying the (humoral) immune
systemdand soon it became clear that there are ways to overcome
it. The hapten concept goes back to the 1930s; a small molecule can
gain antigenicity if it is bound to larger proteins11,12: stable, cova-
lent binding is required to modify the larger protein structure.
Thereby the modiﬁed protein could be a foreign or an endoge-
nously produced protein, towhich tolerance has been developed. In
both instances, the modiﬁed protein becomes a new antigen, as the
stable hapten-binding modiﬁes the protein. The modiﬁed protein
(haptenecarrier complex) can under certain circumstances elicit B-
cell reactions, antibody production and secretion anddafter pro-
cessing to small peptides presented by MHCdT-cell reactions. The
antibody speciﬁcity is often predominantly directed to the small
hapten itself as even a small modiﬁcation of the hapten can alreadyTable 1 Comparison of the hapten and p-i concepts.
Hapten concept p-i concept
Chemical binding to proteins or
peptides
Structural binding to HLA or TCR
Covalent interactions Noncovalent interactions
Often dependent on processing
and metabolism
Processing and metabolism not
required
Activation of the innate immune
system
Bypass of the innate immune systemabrogate the recognition of the whole haptenecarrier complex
(Table 1).12
Haptens are chemicals that are chemically reactive and have a
tendency to build covalent bonds to some AAs within a protein. For
example, at least 13 lysine groups within the albumin molecule
have been shown to bind piperacillin and were processed to
different modiﬁed epitopes within the same protein.13 For the
immune system, accessible modiﬁcations may elicit antibody re-
sponses to these hapten-modiﬁed epitopes. If the antibodies react
with the hapten bound to different sites on the same protein, cross-
linking of the bound antibodies can occur. This requires a certain
sterical distance between these hapten-modiﬁed epitopes, other-
wise the rather large antibody molecule (their Fab part) would
interfere with binding. If the antibody response is predominantly
directed to the hapten and distant enough to allow two antibody
bindings, cross-linking of the hapten-speciﬁc antibodies (including
antibodies with the same speciﬁcity!) can occur by a single protein.
This may enhance and explain why hapten-speciﬁc IgE reactions
are often fulminant and occasionally even fatal.
Later, the work of Landsteiner et al showed that the delayed
reaction to haptens (later shown to be T-cell mediated) is also very
speciﬁc.14 Proteins are processed and presented as small 8e20-AA
long peptides by MHC-encoded molecules, which as proteins
(HLA) appear on the cell surface. Thereby the 14e18 HLA molecules
expressed per individual present different peptides (mostly 8e10
AA for HLA class I, w14e16 AA for HLA class II), which ﬁt into the
peptide binding groove of HLA-molecules. Further work by Welt-
zien et al demonstrated that the location of the haptenmodiﬁcation
(in themiddle or at the end of the 9-mer peptide) may inﬂuence the
functional consequence of the evolving immune response, in
particular cross-reactivity and autoimmunity.15
It is important to realize that hapten-speciﬁc immune responses
are complete immune responses, involving stimulation of anti-
bodies and T-cells. Actually, if a drug is able to elicit both B- and T-
cell immune responses, it is most likely to have hapten-like char-
acteristics. Haptens are immunogenic and antigenic: their immu-
nogenicity is linked to the ability to activate the innate immune
system, mostly by binding to molecules that cause cell activation or
damage. For quite a number of molecules it has been shown that
haptenization leads to the activation of dendritic cells (DCs)
in vitro,16,17 and this capacity of haptens is used to identify contact
allergens by in vitro tools. The immunogenicity is supplemented by
antigenicity, which is the provision of antigenic determinants for
the speciﬁc immune receptors (B- and T-cell receptors).
Not every hapten modiﬁcation may result in an efﬁcient im-
mune response: if, for example, the hapten modiﬁes a peptide
sequence, which is not presented by the available HLA alleles, the
hapten modiﬁcation remains unnoticed by the immune system. If
the hapten induced modiﬁcation does not simultaneously activate
the innate immune system it may remain ignored, as no efﬁcient
immunity will be developed.
An unexplained issue of the hapten (or prohapten) theory is the
fact that hapten-formation is common for given drugs such as
penicillin and happens in the majority of treated patients. IgG
antibody formation to penicilloyl-determinants seems to be
frequent. Why only a minority of patients develops an allergic,
clinically symptomatic immune reaction is unclear.
The prohapten concept
Many drugs are not chemically reactive but are still able to elicit
immune-mediated side effects. The prohapten hypothesis recon-
ciles this phenomenonwith the hapten hypothesis by stating that a
chemically inert drug may become reactive upon metabolism.18,19
Sulfamethoxazole (SMX) is a prototype of such a prohapten. It is
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nicity by a cytochrome p450 dependent metabolism (CYP2C9) in
the liver, where SMX-hydroxylamine is formed. This is also found
extrahepatically, where it is easily converted to SMX-nitroso (SMX-
NO) by oxidation.20 The latter is chemically highly reactive and
binds stably to intracellular proteins (cysteins) creating neo-
antigenic determinants19: this binding to certain intracellular
proteins may also result in cell damage, if SMX is given in high
doses. Thus, SMX (actually SMX-NO) seems to have both antigenic
and immunogenic features. Since many different proteins might be
modiﬁed, the resulting clinical picture might be as variable as with
haptens and SMX is indeed known to cause many different types of
diseases affecting many organs [exanthems, anaphylaxis, Stevense
Johnson syndrome (SJS), hepatitis, blood cell dyscrasia, etc.]. These
side effects are mediated by antibodies and/or T-cells. In contrast,
the conversion of a prohapten to the reactive hapten may occur
exclusively in the liver or kidney and may thus cause an isolated
hepatitis or interstitial nephritis.21 Importantly, the metabolite may
or may not be a hapten. If it not transformed to a hapten, it may
stimulate the immune system like the parent compound (see
allopurinol/oxypurinol).
The p-i concept
A completely different approach to view and analyze the interac-
tion of small molecules with immune receptors is based on the
pharmacological feature of drugs, meaning that small molecules
have a tendency to interact with larger proteins. This feature is
widely exploited in the design of drugs, which are often synthe-
sized with the scope to ﬁt into certain receptors or enzyme pockets
and to block or stimulate them by noncovalent binding. Via this
normal feature of drugs, they may also target immune receptors,
whereby the enormous polymorphism of the highly variable im-
mune receptors makes it rather likely that at least some of the TCRs,
some of the antibodies, or of the HLA alleles bind a drug with a
substantial afﬁnity. While most of these interactions may remain
functionally irrelevant, some data generated over recent years
show that some of the drug bindings to immune receptorsmay lead
to an unusual stimulation of the immune system (Table 1).
Deﬁnition of p-i
The concept of drug interactionwith immune receptors is called the
p-i concept, meaning pharmacological interactions of drugs with
immune receptors. According to the p-i concept, chemically inert
drugs, unable to covalently bind to peptides or proteins, can never-
theless activate certain T-cells, if they ﬁt with a sufﬁcient afﬁnity into
some of the various T-cell receptors or MHC-molecules available. This
reversible interaction is similar to the one of a ligand to its receptor.8e10
One has to emphasize that it is a (noncovalent) drug binding to
receptors based on van der Waals, electrostatic forces, or hydrogen
bonds. The consequences of drug binding to either HLA or TCR
might be quite distinct (see below).22 As the reactive cells are im-
mune cells, the functional consequences of this pharmacological
action result in immune stimulations (or blockade). This does not
mean, however, that the immune stimulation by binding a drug to
immune receptors is based on an immune response, which is the
result of a complex interplay of various cells and receptors. Indeed,
the drug interaction with immune receptors is not a typical im-
mune response or a consequence of recognition by speciﬁc immune
receptors, as it occurs with protein antigens. The terminology
recognition, as it is normally used to deﬁne the interaction of im-
mune receptors with its antigen, is misleading in p-i. In p-i, binding
of a drug and not of an antigen takes place; thus, the antigen is not
an antigen and many controls of immune activations by an antigenare bypassed. In addition, the activation may have unusual features
(see below). Actually, as the drug is designed for other purposes, the
p-i based stimulation of immune receptors is a classical, unin-
tended off-target effect of a drug.
The p-i concept was developed using drug speciﬁc human Tcells
(T-cell clones; TCC).6,23e26 It has not been used to explain B-cell
stimulations or stimulations of Fc-receptor bearing cells by inter-
acting with Fc-receptor bound antibodies. This is considered un-
likely. At present it is unclear whether interactions of labile bound
drugs to a serum protein (by multiple hydrogen bonds etc.) can
form a complex stable enough to interact with antibodies and
whether this results in an efﬁcient signaling to B cells. It is also
unclear whether such a labile drugeprotein complex can cross-link
antibody molecules on Fc-receptors and thus cause cell activation.
Nevertheless, one should be aware that positive immediate skin
tests or basophil activation tests elicited by chemically inert, small
drugs are documented and are not explained by the prevailing
hapten concept.
A short history of the p-i concept
TCCs were ﬁrst generated to penicillin G,27e29 SMX,6,24 and lido-
caine.30 These TCCs were very speciﬁc, could be generated within
weeks from patients with respective allergies and small modiﬁca-
tion of the drug abrogated reactivity. Analysis of SMX and
lidocaine-reactive Tcells made it clear that the stimulation of T cells
by some drugs did not follow the rules described for classical
protein antigens or haptenecarrier constructs: (1) Aldehyde-ﬁxed
antigen-presenting cells (APC; EpsteineBarr virus transformed
autologous B-lymphoblastoid cell lines) were still able to activate
TCCs, which speciﬁcally reactedwith a drug (lidocaine, SMX).23,25,31
Since ﬁxed APCs are unable to take up the drug, it showed that no
metabolism of the drug to a reactive compound nor processing of a
drug modiﬁed protein antigen to a hapten-peptide was required to
elicit TCC activation, as one would expect for hapten reactions or
normal protein antigens. (2) Covalently bound haptens (such as
penicillin G) are not removed from the drug (e.g. penicillin) pulsed
APC by washing. In contrast, washing of APC incubated with lido-
caine and SMX abrogates the reactivity to these drugs: this was
interpreted as illustrating the lability of drug binding to its im-
mune-receptors.23,30 This feature of the p-i concept made certain
biochemical studies or studies with radioactive labeled drugs
impossibledand remains one of the main reasons for skepticism of
the p-i concept; recent datawith abacavir reveal that this particular
drug binds with sufﬁcient afﬁnity to the F-pocket in HLA-B*57:01
and is not washed away.7,32 However, this high afﬁnity binding of a
drug by noncovalent bonds is the exception and not the rule. (3)
Calcium inﬂux in TCCs happens within seconds (20e100 seconds)
after the addition of the drug to the mixture of drug-speciﬁc TCCs
and APCs.25,32 This time interval is too short to allow uptake,
metabolism, processing of modiﬁed proteins to immunogenic
peptides and presentation of modiﬁed peptides. (4) Blocking of
drug metabolism or processing to peptides within APCs does not
interfere with TCC stimulation; e.g. in the case of abacavir stimu-
lation of TCCs, abacavir metabolizing enzymes are not expressed in
immune cells and inhibition of metabolism or of proteasome in
APCs does not affect TCC reactivity.32 (5) Transfection of the TCR
into hybridoma cells (not expressing human MHC) shows that: the
drug speciﬁcity is due to a (transfected) speciﬁc TCR; both chains of
the TCR are needed for signaling; and that interaction with HLA
molecules presented on APC are required for full activation.7,33
Functional analysis of TCC revealed some peculiar features34,35: (1)
Some CD4þ TCC are MHC class I restricted; some CD8-TCC are MHC
class II restricted.23,26 (2) Quite a large proportion of drug-speciﬁc
TCCs simultaneously express CD4 and CD8; while an effect of cell
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positive T cells, the frequency of such reactions is substantially
higher in drug compared to peptide speciﬁc cultures/TCCs. In
addition to SMX and lidocaine, carbamazepine (CBZ)- and
lamotrigine-speciﬁc TCCs were often double positive.36,37 (3) A
high proportion of CD4þ TCCs are cytotoxic: killing is mediated by
FasL, but also by granzymeB and perforin23,38,39; however,
granulysin-mediated killing is rare in CD4þ T cells. (4) Elution and/
or exchange of peptides presented by HLA-DR does not affect TCC
reactivity in some SMX speciﬁc TCC26; and some lidocaine and SMX
speciﬁcs have been shown to be HLA-dependent, but not HLA-allele
restricted in drug stimulations: different alleles are sufﬁcient to
stimulate the TCC.26,35 (5) Of SMX speciﬁc CD4þ TCCs, 27% are
alloreactive: these TCCs are stimulated by alloalleles without add-
ing SMX,meaning that the TCC also has a certain peptide speciﬁcity.
This occurrence of alloreactivity is substantially higher compared to
peptide speciﬁc TCC (<5%).35 (6) Many TCCs are self-presenting,
meaning that the activated T cells, which express MHC class II,
are already sufﬁcient to activate the TCCs (in the absence of exog-
enously added APCs).35
These data prompted the development of the p-i concept8e10 to
explain these puzzling features.
One typical clinical feature of p-i is that the clinical effect is
restricted to T cell reactions: there are no descriptions of anaphy-
laxis to classical p-i reacting drugs such as CBZ, phenytoin, and
lamotrigine, although these drugs have obviously a high potential
to stimulate the immune system. It is doubtful whether B cells are
activated by these drugs, and the activation of the innate immune
system and activation of DCs is also often questionable; if it hap-
pens, it might occur as a consequence of prior, direct drug-induced
T-cell stimulation. Other drugs such as SMX may act mainly via p-i,
but may occasionally also elicit anaphylaxis, as hapten responses
are also occurring (to SMX-NO).
Direct p-i (p-i TCR)
Full T-cell activation by the drug (measured by immediate Ca2þ
inﬂux into speciﬁc T-cells, cytokine synthesis and proliferation)
requires the interaction of the TCRs with MHC (documented for
MHC class II) on APCs. This was proven by testing hybridoma cells
of mouse origin (devoid of human MHC), which were transfected
with drug (SMX or quinolone) speciﬁc TCR: they did not mount a
full response (IL-2 secretion) to addition of the drug. Only if APCs
with human MHC were provided, did they react.7,33
The data also raise the question of whether the drug binds ﬁrst
to the MHC molecule (p-i HLA), modifying its structure and thus
leading to speciﬁc T-cell activation (¼ indirect p-i), or whether the
drug binds primarily to speciﬁc TCRs, rendering the MHC interac-
tion a necessary, but only supplementing signal (p-i TCR, direct p-i).
Initial data suggest that the interaction of the drug happens ﬁrst
with the TCR, since in SMX and lidocaine models the MHC-bound
peptide could be exchanged or removed without affecting CD4þ
T-cell activation.35,39 Moreover, some TCCs react to the drug even in
the presence of allogeneic MHC molecules, indicating that no strict
HLA restriction for SMX or lidocaine presentation exists.31,35
Indeed, a recent study showed that in certain SMX speciﬁc TCCs,
other, structurally related sulfanilamides may block the stimulation
of SMX.40 Docking studies have revealed that these blocking sul-
fanilamides bind to the same site as SMX (CDR3), but without
signaling. Other TCRs/TCCs are also reactive with SMX, but the
cross-reactivity with sulfanilamides differs by: (1) combining the
reactivity and cross-reactivity to SMX and 11 related sulfanilamides
(proliferation and Ca2þ inﬂux) of two TCRs/TCCs; (2) comparing the
structure of the reactive TCR; (3) evaluating blocking of SMX
stimulation by other sulfanilamides; and (4) docking studies ofSMX and sulfanilamides to different TCRs whereby a rather clear
picture emerged which identiﬁed the involved sites on the SMX-
speciﬁc TCR.40 They were on the variable region of the CDR2 or
CDR3 region and were absent on other TCRs, which were not SMX
reactive. Moreover, comparing the twomodel TCRs reveals that TCC
1.3, which is stimulated by SMX only, binds to CDR3, which is in the
interphase of TCR and peptide-MHC. It directly activates the T cell.
In contrast, in TCC H13 the binding site is located outside of the
peptide-MHC interacting region. The SMX binding on CDR2
induced an allosteric modiﬁcation, with structural changes
enhancing TCR-peptide interactions.41
Another example is the important role of a certain TCR clono-
type in CBZ hypersensitivity. Patients with CBZ-induced SJS/toxic
epidermal necrolysis (TEN) and HLA-B*15:02 background react to
normal peptides, and not against a hapten-modiﬁed peptide.42 The
T cells use the TCR V-11-ISGSY clonotype.43 This clonotype was
present in 16 of 19 patients and absent in all 17 CBZ-tolerant pa-
tients. CBZ-speciﬁc cytotoxicity could be primed in vitro in the
PBMCs of healthy individuals who are carriers of HLA-B*15:02 and
VB-11-ISGSY. These data show that, in addition to B*15:02, the TCR
sequence may be crucial for disease manifestations. Although no
direct interaction of the drug (CBZ) with the TCR was found, the
data suggest that CBZ as drug itself or a peptide induced by CBZ are
involved in the selection and stimulation of T cells. It may be that
only if both a certain HLA and a certain TCR sequence are present
that a strong and disease-causing stimulation develops.Indirect p-i, (p-i HLA)
A decisive step forward in understanding severe, T-cell-mediated
DH reactions was the description of a strikingly high HLA-B-allele
association44e46 for certain severe DH reactions. The HLA-allele
associations are extremely high, with a negative predictive value
close to 100%; this is linked to the reaction to a particular drug, and
mostly linked to severe reactions. The frequency of the involved
allele in the population is important for linkage associations.47
The strong association raises the question of whether this
linkage is due to the allele itself or the presented peptide. Elution of
the peptide shows clearly that the peptides are not modiﬁed,
neither in CBZ nor in abacavir hypersensitivity reactions.3e5,42 In
the case of HLA-B*57:01 linked abacavir hypersensitivity4,48 the
binding of abacavir to the F-pocket can be shown by crystallog-
raphy.4 A similar binding cleft can be identiﬁed for CBZ, which
binds to HLA-B*15:02, an allele rather common in southeast Asia
and probably responsible for the high occurrence of SJS/TEN due to
CBZ in these regions.4,45 Thus, p-i (HLA) can be veriﬁed by various
means and for different drugs.Altered peptide model
What is the consequence of drug binding to HLA? In principle, two
possibilities exist: the drug may alter the peptide presented
(altered peptide repertoire),3e5 or the drug may, by binding to HLA,
alter the whole immunogenic conformation (altered HLA).
Recent studies on abacavir hypersensitivity have not only shown
that abacavir can bind by noncovalent bonds in the F-pocket of the
HLA-B*57:01 groove, but also that this binding can evenmodify the
peptide binding properties of HLA-B*57:01.3e5 These in vitro
studies have been done using rather high concentrations of aba-
cavir (100 mg/mL). Three different groups showed that in the
presence of abacavir more peptides harboring a small aliphatic
anchor residue at the C-term are loaded, leading to an altered
peptide repertoire. About 20% of eluted peptides were altered
peptides. These studies also suggest that not abacavir but an altered
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lating a possible link between DH and autoimmunity.
It should be noted that the concept of altered peptide presen-
tation has already been approached from a different viewpoint. In
the search to optimize MHC peptide presentation and to improve
vaccination efﬁcacy, Dickhaut et al described so-called MLEs, which
are small catalytic compounds able to open up the MHC binding
site by triggering ligand-release and stabilizing the receptive state
of MHC class II molecules.2 One such MLE is adamantane ethanol,
but abacavir may have a similar ability on MHC I (B*57:01).Altered pHLA model
A separate extensive analysis of many abacavir reactive TCC chal-
lenges the altered peptide concept and came to a the conclusion
that peptide exchange is not necessary for immunogenicity (32).
Altering the HLA-(self) allele without modifying the peptide
sequence is sufﬁcient for immunogenicity, as drug binding alters
the whole conformation of the HLA-peptide complex (pHLA) as
seen from the TCR and make the self-allele plus self-peptide anti-
genic for T-cells.
The crucial experiment is shown in Figure 1: abacavir binds to
B*57:01 with high afﬁnity and resists washing of abacavir incu-
bated cells. When APC are pulsed with abacavir overnight, it is
internalized and loaded in the endoplasmic reticulum (ER) on HLA
B*57:01 (¼ abacavir pulsing). Ca2þ inﬂux assays reveal that all
abacavir-induced TCCs reacts to these abacavir pulsed APCs, and
some of the reactive TCC required pulsing with only small amounts
of abacavir (1 or 10 ng/mL) to react to the pulsed APC. Some TCCs
react not only after pulsing, which allows abacavir loading onto
empty HLA-B*57:01 in the ER, but also quasi-immediately (within
60e120 seconds), when abacavir is presented on the surface. Full
reactivity to surface loaded HLA requires rather high concentra-
tions (1 or 10 mg/mL), probably because loading on surface-
expressed HLA-B*57:01 is hampered by the already presented
peptides. Thus only TCC, which carried TCR with a high avidity for
the HLAeabacavirepeptide complex, showed a reaction. The data
show that: (1) reactivity of abacavir-induced TCCs to surface aba-
cavir is dependent on the dose of abacavir and density of HLA-
B*57:0132; (2) abacavir can bind to and modify HLA-B*57:01 on the
surface (at 1e10 mg/mL) or in the ER (with 1000-fold lower con-
centrations); and (3) that an altered peptide is not necessary to
induce abacavir reactivity. It is unclear whether the TCCs react to
the same or different peptides, when abacavir loading takes place
in the ER or on the surface.
The ﬁnding that a normal tolerogenic peptide may become
immunogenic, just by altering the presenting (self) allele by the
rather strong drug (abacavir) binding to B*57:01, has major impli-
cations for understanding DH. It needs to be veriﬁed by other drugs.
It candin analogy to altered peptide modeldbe named the altered
pHLA model (Figure 1).Open questions for p-i
The p-i concept is an nonimmunological approach to an immuno-
logical problem, namely how a small molecule interacts with the
immune system. It postulates a pharmacological interaction
without the multiple checkpoints typical for immune reactions
(activation of DCs, costimulation). This feature of p-i could explain
the self-destructive nature of some DH reactions. By contrast, the
possibilities of the immune system to react are limited to immune
reactions and while it appears bizarre, they are partly similar to
normal immune stimulations and have some similarities to virus
stimulations, or occasionally to graft-versus-host or superantigenstimulations. Differentiating p-i TCR or p-i HLA also raises several
points (see below).
p-i stimulation of preactivated cells
Already by conceiving the p-i concept it was enigmatic how a small
molecule might stimulate T cells. This refers mainly to p-i TCR
stimulations, for which initially more data have been accumulated
than for the later elaborated p-i HLA stimulations. Actually, it has
been speculated that only effector/memory cells may react to the
minor signal as drug binding to TCR (p-i TCR), since memory T cells
have a substantially lower threshold for activation than naïve T
cells. This threshold of T-cell activation might be low in the
skin,49,50 where sentinel T cells show indeed a lower threshold of
activation than resting circulating T cells.50 Also a concomitantly
occurringmassive immune stimulation of T cells, as it occurs during
generalized herpes or human immunodeﬁciency virus infections,
or during exacerbations of autoimmune diseases, may be a cofactor
for lowering the threshold of T-cell activation by drugs; such im-
mune processes go along with high cytokine levels and an
increased expression of MHC- and costimulatory molecules on APC
and other cells.51 Consequently, T cells are already preactivated by
the immune stimulation and might be more ready to react to a
minor signal such as binding of a drug to its TCR. This would explain
the high occurrence of drug hypersensitivities in these diseases.
However, experimental data supporting these clinical observations
are still missing.
Multiple DH
About 10% of patients with severe drug allergies develop a second
drug allergy; as recently shown, patients with multiple DH carry in
their blood T-cells with a particular phenotype, similar to herpes-
virus stimulated T-cells.52 However, these individuals were
negative for human herpesvirus-6, EpsteineBarr virus, and cyto-
megalovirus infections. This peculiar cell fraction contains the
precursor T cells for different drugs, while the normal cell fraction
does not contain these precursor cells. This ﬁnding shows that
some preactivation may play a role; and that a neglected risk factor
for DH is the existence of a DHdeither ongoing or in remission.
Costimulation by metabolites
While the p-i concept has been documented for many drugs (SMX,
lidocaine, lamotrigine, CBZ, p-phenylenediamine, quinolones, radio
contrast media, abacavir, ﬂucloxacillin, and more)6,7,23,25,32,36,37,53e
55 in some drug reactions, the metabolites of the parent compound
are often also implicated in DH. Cloning suggests that some of these
TCCs/TCRs are reactive via p-i not only to the parent compound, but
possibly also to a metabolite.56 Some of the implicated metabolites
might be chemically reactive and cause hapten-like stimulations.
Thus, immune reactions might evolve via p-i stimulations and
hapten simultaneously. The reaction to a hapten raises the question
of whether the hapten-characteristic of a drug, with its immunos-
timulatory consequences on innate immunity, might be a cofactor
for some p-i mediated stimulations.19
Differences and similarities of p-i stimulations by various
drugs
In addition to maculopapular exanthems, drug rash with eosino-
philia and systemic symptoms (DRESS), acute generalized
exanthematous pustulosis, SJS/TEN, and some other severe hyper-
sensitivity syndromes were described for drugs that stimulate
in vitro via the p-i concept. Often positive patch tests or delayed
Figure 1 (A) It is assumed that abacavir-induced T-cell clones (TCCs) react with a peptide and not abacavir itself,4 as abacavir binds to the F-pocket with no direct access to the T-cell
receptor for antigen (TCR). However, the doseeresponse curve is at ﬁrst sight suggestive of direct abacavir reactivity.32 How can one explain this? All abacavir-induced TCCs react to
antigen-presenting cells (APCs), which were pulsed with abacavir over night. A fraction of these TCCs carry TCRs that have enough afﬁnity for the human leukocyte antigens (HLA)-
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Table 2 p-i stimulations: characteristics of clinical and immunological features of some well-deﬁned drug hypersensitivity reactions.
Abacavir Flucloxacillin Allopurinol Sulfamethoxazole Carbamazepine
HLA association B*57:01 B*57:01 B*58:01 No Han Chinese: B*15:02,
Japanese & European:
A*31:01
Phenotype drug-
speciﬁc cells
CD8 CD8 (predominant)
/CD4
Mainly CD8 CD4, (CD8) Mainly CD8
TCC reactivity with
pulsed APC
Immune response
elicited
No response No response No response No response
Self-presenting
TCL/TCC
Minority Majority-all All Occasionally Occasionally
Characterization of
binding to HLA
Stable binding
(persistent after
washing)
Labile binding (not
persistent after
washing)
Labile binding
(not persistent after
washing)
?; labile to TCR Rather labile (?)
Activation of DC No Hapten ? ?, controversial No
HLA binding site F9 pocket/ normal or
altered peptide
Unknown Unknown No B*15:02, D- pocket
Activation of TCC Immediate (10 mg) and
10 ng after internal HLA
loading
Immediate to fast
(maximum after
5e7 min)
Immediate Immediate ?
Proposedmechanism of
T-cell stimulation
p-i, altered peptide or
altered pHLA
p-i in HLA-B*57:01þ
individuals, hapten in
HLA-B*57:01-
individuals
p-i SMX-NO/ hapten,
SMX/ p-i (TCR)
Requirement of speciﬁc
clonotype
Clinical manifestation Abacavir
hypersensitivity
syndrome
DILI in B*57:01 (but
nephritis, exanthema
with other alleles)
Han Chinese, Thai: SJS/
TEN; Caucasian: SJS
Rash, SJS/TEN, DRESS SJS/TEN
PPV for disease in risk
population
55% 1e2% (?) 1.52% Not known Han Chinese: 3%/ 5.6%
T-cell receptor
repertoire
Polyclonal Polyclonal Polyclonal (oligoclonal) Polyclonal (oligoclonal) VB11, VA22 more
frequent (Han Chinese)
/ VB-11-ISGSY in 84%
of patients with SJS/TEN
Cross-reactivity None Hapten, p-i ?? No, not even with
oxypurinol
Depends on the TCR: from very
restrictive to extensive with
other sulfanilamides
With
oxycarbamazepine or
metabolites
APC ¼ antigen-presenting cells; DILI ¼ drug-induced liver injury; DRESS ¼ drug rash with eosinophilia and systemic symptoms; HLA ¼ human leukocyte antigens;
pHLA ¼ peptide HLA complex; p-i concept ¼ pharmacological interaction with immune receptor concept; PPV ¼ positive predictive value; SJS/TEN ¼ StevenseJohnson
syndrome/toxic epidermal necrolysis; SMX ¼ sulfamethoxazole; TCC ¼ T-cell clones; TCL ¼ T-cell lymphocyte; TCR ¼ T-cell receptor for antigen; ? ¼ non-determined.
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formation tests could be found. The reactivity in skin or in vitro tests
often appears very similar between p-i or hapten-stimulated drugs
and cannot be differentiated by the clinical picture alone. The
clinical symptoms by the p-i drugs may appear more rapidly and
some severe reactions such as SJS/TEN, DRESS, or hypersensitivity
syndromes are clearly p-i related. In addition, the concentration of
the drug isdlike in other pharmacological reactionsddecisive for
the clinic in p-i reactions. It is not infrequent that DRESS symptoms
arise after increasing the dose.
A summary of the best deﬁned p-i acting drugs and their pe-
culiarities is given in Table 2. In some, the afﬁnity of drug binding to
HLA may be crucial (illustrated by abacavir), other drugs may be
presented by various HLA-alleles but with different afﬁnity and
severity (CBZ, allopurinol), in B*58:01 associated allopurinol hy-
persensitivity the metabolism to oxypurinol is required,57 in SMX
and CBZ, the binding to TCR is important, and in ﬂucloxacillin notabacavir/peptide complex, if abacavir is added on the surface to cells; these can react immed
dose and HLA concentration. However, all abacavir induced TCCs, including the high afﬁni
concentrations (1 ng/mL). (Figure reproduced from reference 32, with permission.) (B) Loadi
molecules were not yet loaded with peptides-p. If abacavir is added to APCs on the surface,
abacavir access to the F-pocket. Loading on the surface is thus suboptimal and only high av
react. The immediate reactivity of the abacavir induced TCC is not compatible with a reacti
induced TCCs react either with abacavir itself (unlikely) or in the presence of abacavir with n
peptide exchange) induces reactivity: this model is called altered pHLA model. As the TCC rea
for very high concentrations only, is unclear. The normal peptide was presented by surface-l
same, endogenous peptide or to different peptides, is at present unclear. It is possible th
alloreactive T cells (polyspeciﬁcity).the hapten, but the p-i stimulation may be decisive for liver dam-
age. Altogether, the p-i stimulating drugs vary considerably
(Table 3).
Abacavir (ABC) binding to B*57:01 differs from other drug
binding by its high afﬁnity to the HLA-B*57:01. Abacavir is not
washed away by incubating it with B*57:01þ cells. It is very se-
lective for abacavir, but not for similar nucleoside analogues.
B*57:01 has a high positive predictive value of 47.6% for abacavir
hypersensitivity manifestations), if the patient is patch test posi-
tive. This high association of B*57:01 and hypersensitivity mani-
festations might be related to the high afﬁnity interaction of
abacavir with B*57:01. Abacavir reactivity may appear as early as
1e3 days after treatment started, and is detected after 2 weeks
culture in every B*57:01þ individual, indicating a rather high
precursor frequency.58 No other allele, even B*58:01, has been
linked to abacavir hypersensitivity, where the difference between
B*57:01 and B*58:01 is only one AA in the peptide binding groove.iately (60e100 seconds) to APCs plus abacavir. Their reactivity is dependent on abacavir
ty TCC, also react to abacavir pulsed APCs, even when using 1000-fold lower abacavir
ng of abacavir onto HLA-B*57:01 is easier in the endoplasmic reticulum (ER), when HLA
the HLA-B*57:01 are already ﬁlled with peptides, which competed and partially blocks
idity TCCs that are sufﬁciently stimulated by a few HLAeabacavirepeptide complexes
vity to altered peptide,3e5 as the time did not allow peptide exchange. Thus abacavir-
ormal peptide as well (pHLA). Simple modiﬁcation of HLA by abacavir binding (without
cts with normal peptide on abacavir altered HLA, the role of altered peptides, described
oaded or ER-loaded abacavireHLA complexes. Whether the TCC do always react to the
at different peptides were recognized by the same TCCs, which is not uncommon in
Table 3 Differences and peculiarities in various p-i related drug reactions.
Abacavir The peptide and not the drug is causing the immune reaction; for example altered peptide and altered HLA-allele model
Carbamazepine The presence of a certain TCR-clonotype able to be stimulated by carbamazepine (or the peptide) might represent the missing link between
B*15:02 carriers with and without disease manifestations
Flucloxacillin Hapten and p-i can occur together and result in different clinic; the hapten-based reactions may be responsible for milder symptoms, while the
p-i stimulations may be involved in the HLA B*57:01 linked DILI
Allopurinol Metabolism may play role in p-i reactions as well; if the metabolite is stable, the metabolite (oxypurinol) and not the parent substance might be
linked to HLA and hypersensitivity
Sulfamethoxazole Sulfonamides may cause p-i TCR, which are HLA-allele independent: the binding sites for SMX on some TCR have been identiﬁed and can be
related to binding of other sulfonamide and their functionality (stimulatory or blocking effect)
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binding of abacavir to B*57:01 can inﬂuence the peptide
repertoire presented: if high abacavir concentrations are used
(100 mg/mL, which substantially exceeds the normal plasma con-
centrations of abacavir of 3.3 mg/mL) up to 20% of peptides eluted
from B*57:01/abacavir differ from the normal B*57:01 peptide
repertoire.3e5 However, no convincing data are yet available that
these altered peptides elicit a T-cell response. Moreover, as shown
by Adam et al32 and discussed above (Figure 1), abacavir may
simply modify the B*57:01 structure without removing the pep-
tide: this altered pHLA is in itself already sufﬁcient to cause a
massive immune stimulation, both when abacavir binding to
B*57:01 occurred on the cell surface or in the ER (altered pHLA
model). Re-exposure to abacavir in B*57:01þ individuals with prior
hypersensitivity can lead to a fulminant, lethal hypersensitivity
reaction with rapid destruction of liver, lung tissue, etc. Of note,
there are also some minor, less severe hypersensitivity reactions in
B*57:01 negative individuals as well. Their pathomechanism has
not yet been deciphered.
CBZ can bind to HLA B*15:02, but also to B*15:11 and A*31:01. If
the B*15:02 is present in the population, side effects are mainly
B*15:02 associated.59 CBZ binding is not as exclusive as that of
abacavir, as some cross-reactivity to CBZ-metabolites has been
described in B*15:02. If the B*15:02 allele is not prevalent, asso-
ciation with other alleles such as A*31:01 or A*15:11 appear
(Japanese, Europeans). Whether the immune reaction is similar to
B*15:02 driven reactions is not yet clear.
The interaction with B*15:02 seems to be rather strong, but has
less afﬁnity than the one with abacavir. Docking studies have
placed CBZ in the middle of the peptide binding groove, at the
secondary anchor residue. It can also induce presentation of altered
peptides, which was observed in about 15% of peptides presented
(4). Thus, it might, like abacavir, actually induce a peptide response.
The T-cell response to CBZ in B*15:02þ individuals seems to be
oligoclonal.43 It has been reported that only if a certain TCR-
clonotype is available, does a strong cytotoxic immune response
to CBZ develop. This clonotype (VB-11-ISGSY) is also present in
healthy individuals; such cells could be primed to develop into
cytotoxic T-cells by CBZ exposure (59). The example illustrates
nicely that some drugs may develop immune stimulations by
binding to HLA and TCR.
McCluskey et al has also postulated a possible role of altered
peptide presentation in CBZ-induced B*15:02-linked hypersensi-
tivity reactions.4 However, no data demonstrating a T-cell reaction
to the altered peptide have been obtained so far. Thus, while the
possibility of altered peptide presentation is well documented (at
least for abacavir), actual relevance and the in vivo role of altered
peptide presentation is not yet well documented.
Flucloxacillin is a penicillin derivative and actually a typical
hapten. Flucloxacillin binds covalently to selective lysine residues
in albumin in a time-dependent manner.13,60 Multiple binding sites
of ﬂucloxacillin to various lysines within albumin have been found,
and modiﬁcations of albumin by ﬂucloxacillin could be detected inall treated patients studied to date. Multiple modiﬁed epitopes may
induce immune reactions, which are presented by various HLA-
alleles. Thus it is difﬁcult to link the hapten characteristic to a
single HLA-allele. While the clinical picture of ﬂucloxacillin allergy
is heterogeneous (exanthem, interstitial nephritis), ﬂucloxacillin-
induced liver injury is linked to B*57:01. Interestingly, exactly this
allele has been shown to present ﬂucloxacillin via p-i and not via
hapten, suggesting a link between p-i presentation and severe
ﬂucloxacillin-induced liver injury. Thus, a hapten characteristic
does not exclude p-i presentation as well.
Allopurinol is a main cause of SJS/TEN in Europeans. It is
strongly linked to B*58:01 in Chinese and somewhat less in Euro-
peans, where only 60% express this allele. Thus, other alleles are
also involved. Allopurinol is rapidly metabolized to oxypurinol, and
in vitro analysis of affected patients has shown that oxypurinol is
the relevant antigen.57 Dose seems to be a crucial factor in devel-
oping these sometimes severe side effects. The immune response is
due to p-i HLA, and is mainly directed to oxypurinol.57
SMX is a drug that causes a variety of hypersensitivity reactions,
which are not known to be HLA-allele linked. It is a typical pro-
hapten, and some side effects appear to be linked to hapten feature
of this drug (SMX-NO), while in other reactions like the DRESS
syndrome by SMX or sulfapyridine (the relevant component of
sulfasalazine) hypersensitivity reactions are caused by direct
binding to TCRs.6,7,23,26,40,41 Thus, these reactions are p-I TCR
mediated; the binding site of SMX (and other sulfanilamides) in
two SMX-speciﬁc TCC has been identiﬁed by blocking and docking
studies on the CDR2 and CDR3 regions of the TCR and by molecular
dynamics modeling.40,41 Binding may result in signaling (with Ca2þ
inﬂux and proliferation, if interaction with HLA is possible). Sur-
prisingly, the T-cell reactions are often polyclonal at the start, but
SMX, and other drugs (e.g. iodixanol) may occasionally cause an
oligoclonal or even monoclonal T-cell outgrowth.54
Conclusion
Taken together, the p-i concept suggests that some drug allergies are
pharmacological off-target reactions and not true allergies. Drugs
are able to interfere with the human immune system not only as an
antigen (namely as hapten coupled to a carrier molecule), but also
by pharmaceutical means, namely by drug acting on (immune)
receptors. The dogma that small chemicals are not full antigens is
still valid and must not be refused, but DH-like reactions can occur
also by simple pharmacological means, namely by stimulation of
drug binding to (immune) receptors such as HLA or TCR.
From a general perspective, DH reactions and the underlying p-i
concept demonstrate certain limitations of modern medicine: DH
is, like graft-versus-host diseases or transplant rejections, an un-
usual (or, better, unnatural) way of immune stimulation, which was
not foreseen in the natural evolution of the immune system. The
immune system was neither prepared for the wide use of chem-
icals/drugs, nor was the immune system prepared that humans will
transplant organs. In a certain sense, DH is, like transplantation
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medicine. However, these limitations may be overcome by a better
understanding of the molecular mechanism of DH. Indeed, as
recently shown for abacavir and carbamazepine hypersensitivity,
the use of HLA-B*57:01 or -B*15:02 typing in risk populations can
drastically reduce the incidence of new hypersensitivity re-
actions.61,62 It thus nicely illustrates how understanding leads to a
better clinical practice, which we owe our patients particularly in
an iatrogenic disease such as DH.References
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